Up until 2010, paravalvular aortic regurgitation (pAR) of any severity was diagnosed in 70-90% of patients after transcatheter aortic valve implantation (TAVI) using either a self- or balloon-expanding prosthesis; moderate to severe pAR was observed in 10-30%1. During the last two years, moderate to severe pAR has been documented in 0-12% of patients undergoing TAVI (Figure 1), including those patients implanted with the Medtronic CoreValve (Medtronic, Minneapolis, MN, USA), a valve which has not undergone significant iterations until recently. What can explain the significant reductions in pAR over time?
Figure 1. Rates of significant paravalvular aortic regurgitation (>2+) across various transcatheter ...
Department of Interventional Cardiology, McGill University Health Centre, Montreal, Quebec, Canada
Sign in to read and download the full articleForgot your password?
No account yet? Sign up for free!Create my pcr account
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Read next articleHybrid intravascular imaging: the key for a holistic evaluation of plaque pathology